The aim of the study was to study the effect of the neuropeptide drug Semax on the body weight of white rats in experimental diabetes mellitus. Materials and methods. Experimental studies were conducted on 30 individuals of white rats (males of 8 months of age). The animals were divided into 3 groups (n = 10): control individuals (control); animals with experimental diabetes mellitus (diabetes mellitus); individuals with diabetes mellitus who received intraperitoneal Semax (diabetes mellitus + Semax). Diabetes mellitus was modeled by a single administration of alloxan at a dose of 100 mcg/kg/day. Semax was administered at a dose of 100 mcg/kg/day for 30 days, starting from 21 days after the administration of alloxan. The mass of rats was determined before the introduction of alloxan, at 7, 14, 21 and before the animals were removed from the experiment. The results of the study. A week after the introduction of alloxan, there was a decrease in the body weight of animals in the groups «diabetes mellitus» and «alloxan» by 15%; two weeks laterby 19% and three weeks laterby 26% compared with the control. At the end of the experiment, there was a decrease in the weight of animals in the group «diabetes mellitus» by 31% and in the group «diabetes mellitus + Semax» - by 18% relative to the control; in the group «diabetes mellitus + Semax» - an increase in weight by 16% compared with the group «diabetes mellitus». Conclusion. The results obtained showed that the introduction of the neuropeptide drug «diabetes mellitus + Semax» contributes to an increase in animal body weight against the background of experimental diabetes mellitus, which indicates the correction of protein breakdown processes, namely, an increase in protein biosynthesis.
neuropeptides, semax, experimental diabetes mellitus, anabolic effect
1. Lau L. H., Lew J., Borschmann K., Thijs V., Ekinci E. I. Prevalence of diabetes and its effects on stroke outcomes: A meta-analysis and literature review // J Diabetes Investig. 2019. Vol. 10, no. 3. P. 780-792. doi:https://doi.org/10.1111/jdi.12932.
2. Einarson T. R., Acs A., Ludwig C., Panton U. H. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017 // Cardiovasc Diabetol. 2018. Vol. 17, no. 1. R. 83. doi:https://doi.org/10.1186/s12933-018-0728-6.
3. Harding J. L., Pavkov M. E., Magliano D. J., Shaw J. E., Gregg E. W. Global trends in diabetes complications: a review of current evidence // Diabetologia. 2019. Vol. 62, no. 1. R. 3-16. doi:https://doi.org/10.1007/s00125-018-4711-2.
4. Havinson V. H., Popovich I. G., Ryzhak G. A., Safarova G. L., Vershinina E. A. Lekarstvennye peptidnye preparaty v aspekte dokazatel'noy mediciny // Patogenez. 2021. T. 19, № 1. S. 19-29. doi:https://doi.org/10.25557/2310-0435.2021.01.19-29.
5. Shormanov I. S., Kosenko M. V., Petrovskiy A. K., Petrovskaya A. Yu., Andreeva L. A., Fedorov V. N., Vorchalov M. M. Farmakologicheskaya podderzhka adaptivnyh vozmozhnostey organizma v usloviyah eksperimental'nogo operacionnogo stressa // Medicinskiy vestnik Bashkortostana. 2016. T. 11, № 2(62). S. 47-52.
